Hypofractionated stereotactic radiotherapy in medium-sized to large arteriovenous malformations. Issue 6 (June 2015)

• Record Type: Journal Article
• Authors: Lindvall, Peter; Grayson, David; Bergström, Per; Bergenheim, A. Tommy
• Is Part Of: Journal of clinical neuroscience. Volume 22:Issue 6(2015:Jun.)
• Page Start: 955
• Page End: 958
• Publication Date: 2015-06
• Subjects: Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2014.12.015
• Languages: English
• ISSNs: 0967-5868

Abstract

<abstract xml:lang="en" abstract-type="author" id="ab005"> <title id="st050">Abstract</title> <sec> <p id="sp0005">We have reviewed treatment results in terms of obliteration and complications in 24 patients with medium to large sized cerebral arteriovenous malformations (AVMs) (mean volume 18.5 ± 8.9 cm³; range: 10–42) treated with hypofractionated stereotactic radiotherapy (HSRT). AVMs are congenital lesions associated with a high morbidity and mortality. Radiosurgery is one option for treatment. However, in larger AVMs with volumes exceeding 10 cm³ obliteration rates are less favourable and radiation induced complications more frequent. For larger AVMs, volume-staged radiosurgery is one option while another option may be the use of HSRT. Patients were treated with 6–7 Gy in five fractions to a total dose of 30–35 Gy (mean total dose 32.9 ± 1.6 Gy [standard error of the mean]). Sixteen patients (69.6%) showed obliteration after a mean time of 35.2 ± 14.8 months (range: 24–60). Only one patient (4.2%) experienced symptomatic radionecrosis. Our treatment with HSRT seems safe and efficient for treatment of medium to large sized AVMs. Treatment results seem to be in line with volume-staged radiosurgery and may be an alternative for AVMs not suitable for single fraction radiosurgery.</p> </sec> </abstract>